Breast Cancer Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)

Breast Cancer Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)

DelveInsight’s, “Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 120+ Breast Cancer companies and 130+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Breast Cancer Pipeline Report

  • DelveInsight’s Breast Cancer pipeline report depicts a robust space with 120+ Breast Cancer companies working to develop 130+ pipeline therapies for Breast Cancer treatment.
  • The leading Breast Cancer Companies working in the market include Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
  • Promising Breast Cancer Pipeline Therapies in the various stages of development includes Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.
  • December 2023: Cancer Insight LLC announced a study of Phase 2 clinical trials for Trastuzumab and GM-CSF. In this study, the investigators intend to assess the ability of the combination of trastuzumab and the HER2 vaccine nelipepimut-S (administered with the immunoadjuvant GM-CSF) given in the adjuvant setting to prevent recurrences in patients with high-risk HER2-positive breast cancer. High-risk is defined as those patients that do not achieve a pCR after neoadjuvant therapy with an approved regimen that includes trastuzumab and at least four cycles (12 weeks) of taxane-containing chemotherapy or those who undergo upfront surgery and are found to have greater than or equal to four positive lymph nodes regardless of hormone receptor status or 1-3 positive lymph nodes and are hormone receptor negative.
  • December 2023: Seagen Inc. announced a study of Phase 3 clinical trials for Tucatinib, Trastuzumab and Pertuzumab. This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.
  • December 2023: AstraZeneca announced a study of Phase 3 clinical trials for Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin and Cyclophosphamide. This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

  

Request a sample and discover the recent advances in Breast Cancer Treatment Drugs @ Breast Cancer Pipeline Outlook Report

 

The Breast Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Breast Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Breast Cancer clinical trial landscape.

 

Breast Cancer Overview

Breast cancer is the most common cancer diagnosed in women, accounting for more than 1 in 10 new cancer diagnoses each year. It is the second most common cause of death from cancer among women in the world. Anatomically, the breast has milk-producing glands in front of the chest wall. They lie on the pectoralis major muscle, and there are ligaments support the breast and attach it to the chest wall. Fifteen to 20 lobes circularly arranged to form the breast.

 

Find out more about Breast Cancer Treatment Landscape @ Drugs for Breast Cancer Treatment

 

Breast Cancer Emerging Drugs Profile

  • SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
  • HLX11: Shanghai Henlius Biotech
  • Praluzatamab ravtansine: CytomX Therapeutics
  • MCLA-128: Merus N.V.
  • DX126 262: Hangzhou DAC Biotech

 

Breast Cancer Pipeline Therapeutics Assessment

There are approx. 120+ key Breast Cancer companies which are developing the Breast Cancer therapies. The Breast Cancer companies which have their Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine Co., Ltd.

 

DelveInsight’s Breast Cancer pipeline report covers around 130+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Breast Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Breast Cancer Pipeline Therapies @ Breast Cancer Clinical Trials Assessment

 

Scope of the Breast Cancer Pipeline Report

  • Coverage- Global
  • Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Breast Cancer Companies- Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, and others.
  • Breast Cancer Pipeline Therapies- Oraxol, ARV-471, Ribociclib, E7389, Trastuzumab, GM-CSF, GM-CSF, Trastuzumab, Paclitaxel, Gemcitabine/Carboplatin, Iniparib, and others.

 

Dive deep into rich insights for new drugs for Breast Cancer treatment, Visit @ Breast Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Breast Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. MCLA-128: Merus N.V.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. DX126 262: Hangzhou DAC Biotech
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ES2B C001: ExpreS2ion Biotechnologies
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Breast Cancer Companies
  21. Breast Cancer Products
  22. Breast Cancer Unmet Needs
  23. Breast Cancer Market Drivers and Barriers
  24. Breast Cancer Future Perspectives and Conclusion
  25. Breast Cancer Analyst Views
  26. Breast Cancer Companies
  27. Appendix

 

For further information on the Breast Cancer pipeline therapeutics, reach out to Breast Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market


Posted

in

by

Tags: